ClearPoint Neuro, Inc. (CLPT)

NASDAQ: CLPT · Real-Time Price · USD
11.21
-0.57 (-4.84%)
At close: Apr 27, 2026, 4:00 PM EDT
11.25
+0.04 (0.36%)
After-hours: Apr 27, 2026, 7:50 PM EDT
Market Cap336.14M +9.1%
Revenue (ttm)36.97M +17.8%
Net Income-25.54M
EPS-0.90
Shares Out 29.99M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume427,590
Open11.60
Previous Close11.78
Day's Range11.05 - 11.79
52-Week Range8.27 - 30.10
Beta1.18
AnalystsStrong Buy
Price Target20.00 (+78.41%)
Earnings DateMay 8, 2026

About CLPT

ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula. It also provides ClearPoint softwa... [Read more]

Sector Healthcare
Founded 1998
Employees 172
Stock Exchange NASDAQ
Ticker Symbol CLPT
Full Company Profile

Financial Performance

In 2025, ClearPoint Neuro's revenue was $36.97 million, an increase of 17.78% compared to the previous year's $31.39 million. Losses were -$25.54 million, 35.0% more than in 2024.

Financial Statements

Analyst Summary

According to one analyst, the rating for CLPT stock is "Strong Buy" and the 12-month stock price target is $20.0.

Price Target
$20.0
(78.41% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

ClearPoint Neuro Announces FDA Clearance of the Velocity Alpha(R) MR High Speed Surgical Drill System and First Clinical Use, Further Expanding Our Drug Delivery Ecosystem and Global Footprint

SOLANA BEACH, CA / ACCESS Newswire / April 22, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brai...

Other symbols: R
5 days ago - Accesswire

ClearPoint Neuro Announces Canadian Approval for its Navigation System Further Expanding Our Drug Delivery Ecosystem and Global Footprint

Combined clearance of the navigation and drug delivery technologies enables Canadian neurosurgery centers to leverage the Company's flagship image-guidance workflow and advances ClearPoint Neuro's ove...

7 days ago - Accesswire

ClearPoint Neuro Earnings Call Transcript: Q4 2025

2025 saw record revenue growth, a successful IRRAS acquisition, and strong momentum into 2026, with all core segments expected to grow double digits. Guidance for 2026 is $52M–$56M, reflecting FDA and integration factors, and long-term targets remain ambitious.

5 weeks ago - Transcripts

ClearPoint Neuro Reports Fourth Quarter and Full Year 2025 Results

Record Revenue and IRRAS Holdings Acquisition Highlight the Company's 'Fast. Forward.' Strategy SOLANA BEACH, CA / ACCESS Newswire / March 17, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company...

5 weeks ago - Accesswire

ClearPoint Neuro to Announce Fourth Quarter and Full Year 2025 Results March 17, 2026

SOLANA BEACH, CA / ACCESS Newswire / March 6, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the b...

7 weeks ago - Accesswire

ClearPoint Neuro Gets EU Green Light For Updated Brain Surgery Software

ClearPoint Neuro, Inc. (NASDAQ: CLPT) on Friday said it received EU MDR Certification for its ClearPoint Navigation Software Version 3.0.2.

3 months ago - Benzinga

ClearPoint Neuro Announces EU MDR Certification for ClearPoint Navigation Software Version 3.0.2, Expanding Access to the Latest Operating Room Navigation Platform in Europe

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 22, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigati...

3 months ago - Accesswire

ClearPoint Neuro Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue

The Company Achieved 20% Comparable Sales Growth in the Fourth Quarter of 2025 at $10.4 Million SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 12, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (th...

3 months ago - Accesswire

ClearPoint Neuro Completes Acquisition of IRRAS

Acquisition Will Enhance ClearPoint Neuro's Commercial Scale, Drive Operational Leverage, and Support Its Long-Term Strategy in CNS Drug Delivery Innovation SOLANA BEACH, CALIFORNIA / ACCESS Newswire ...

5 months ago - Accesswire

ClearPoint Neuro Reports Third Quarter 2025 Results

Site Readiness Continues for Specialized Treatment Centers Envisioned to Support a Growing Number of Cell and Gene Therapy Trial Patients and Later Commercialization SOLANA BEACH, CA / ACCESS Newswire...

6 months ago - Accesswire

ClearPoint Neuro Announces Agreement to Acquire IRRAS

Acquisition Will Further Expand the Potential of ClearPoint Neuro's Drug Delivery Portfolio While Immediately Adding New Indications and Commercial Scale Across a $0.5 Billion Market for the Treatment...

6 months ago - Accesswire

ClearPoint Neuro Earnings Call Transcript: Q3 2025

Q3 revenue grew 9% year-over-year to $8.9 million with gross margin rising to 63%. The IRRAS acquisition expands access to a $500 million neurocritical care market, and 2026 combined revenue is forecast at $54–$60 million. Integration and new CRO capacity are expected to drive future growth.

6 months ago - Transcripts

ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2025

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / November 5, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigati...

6 months ago - Accesswire

ClearPoint Neuro Announces Promising Results from Brain Tumor Laser Therapy Study to be Presented at the CNS Annual Meeting in Los Angeles

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / October 7, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigatio...

7 months ago - Accesswire

ClearPoint Neuro Announces Expanded International Clearances for Key Therapy Delivery Product; Now Totaling 34 Countries Worldwide

The clearly established history across global regulatory bodies is expected to de-risk BioPharma partners' pathways towards achieving global scale and standardization. SOLANA BEACH, CALIFORNIA / ACCES...

7 months ago - Accesswire

ClearPoint Neuro Announces Development and Demonstration of the Company's Proprietary Robotic Neuro-Navigation System

New Product Category Will Enable Added Flexibility to Support Commercial Launches of Cell and Gene Therapy SOLANA BEACH, CALIFORNIA / ACCESS Newswire / October 1, 2025 / ClearPoint Neuro, Inc. (Nasdaq...

7 months ago - Accesswire

ClearPoint Neuro Announces the Appointment of Dr. Paul Larson as Chief Medical Officer

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / September 25, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise naviga...

7 months ago - Accesswire

ClearPoint Neuro Announces FDA Clearance Expanding Compatibility of the ClearPoint Prism Neuro Laser Therapy System with 1.5T MRI Scanners

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / September 4, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigat...

8 months ago - Accesswire

ClearPoint Neuro Earnings Call Transcript: Q2 2025

Q2 2025 revenue grew 17% year-over-year to $9.2M, driven by strong performance across all segments and record adoption of new products. Cash position strengthened to $41.5M, supporting global expansion and ongoing investments in cell and gene therapy delivery.

9 months ago - Transcripts

ClearPoint Neuro Reports Second Quarter 2025 Results

Record Revenue and Substantial Cash Infusion Highlight the Company's ‘Fast. Forward.' Strategy SOLANA BEACH, CA / ACCESS Newswire / August 12, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company...

9 months ago - Accesswire

ClearPoint Neuro Announces Progression of Key Partner Milestones throughout the Global Biologics and Drug Delivery Portfolio

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / August 4, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to ...

9 months ago - Accesswire

ClearPoint Neuro to Announce Second Quarter 2025 Results August 12, 2025

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / July 23, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation ...

9 months ago - Accesswire

ClearPoint Neuro Reports First Quarter 2025 Results

Record Revenue Highlighted by 70% Growth in Single-Use Navigation and Therapy Products SOLANA BEACH, CALIFORNIA / ACCESS Newswire / May 13, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"),...

1 year ago - Accesswire

ClearPoint Neuro Earnings Call Transcript: Q1 2025

Q1 2025 revenue grew 11% year-over-year to $8.5M, led by strong gains in neurosurgery navigation and biologics. New funding from Oberland Capital ensures multi-year strategic flexibility, while new product launches and a shift to subscription models position the company for accelerated growth.

1 year ago - Transcripts

ClearPoint Neuro Announces Investment of up to $110 Million by Oberland Capital with $33.5 Million Funded at Closing

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / May 12, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation t...

1 year ago - Accesswire